Masimo Rainbow SET is the first and only way for
clinicians to continuously and noninvasively monitor their patients'
carboxyhemoglobin, methemoglobin, and oxyhemoglobin saturation as well
as pulse rate and perfusion index
Irvine, California -March 20, 2007- Atom Medical
Corporation today announced that it has entered into a new agreement
with Masimo that will allow it to incorporate Masimo Rainbow SET
technology into its neonatal and premature infant product lines. Masimo
Rainbow SET is a breakthrough noninvasive blood constituent monitoring
platform that has the promise of measuring many blood constituents that
previously required invasive procedures. Masimo Rainbow SET's initial
application is Pulse CO-Oximetry, the first and only technology
platform capable of continuously and noninvasively measuring
carboxyhemoglobin (SpCO) and methemoglobin (SpMet), in addition to
oxyhemoglobin (SpO2), perfusion index (PI), Pleth Variability Index (PVI) and pulse rate.
Masimo Rainbow SET uses multiple (7+) wavelengths of light housed in
a single, simple-to-apply sensor to accurately determine levels of SpCO
and SpMet-two critical dyshemoglobins, that if not monitored and
treated, has proven to increase morbidity and mortality in a broad
range of clinical settings. This gives clinicians the ability to
accurately determine their patients' true oxygenation status, allowing
for more precise and timely diagnosis and treatment.
Built on the gold-standard Read-Through Motion and Low Perfusion
Masimo SET technology, Masimo Rainbow SET has been designed as an
upgradeable technology platform. Masimo scientists are currently
at work using the data delivered by Rainbow's multiple wavelengths of
light to qualify additional noninvasive parameters, such as total
hemoglobin (SpHb), which are anticipated to be able to be
field-installed on Rainbow-ready monitoring devices through a simple
software upgrade, so clinicians can easily purchase and add them when
they become available.
Barry Matsubara, Chairman and Chief Executive Officer of Atom
stated; "We have enjoyed a long partnership with Masimo. The main goal
of this partnership has been to improve the care of patients our
products touch. We entered into this partnership with Masimo
nearly 10 years ago because we believed Masimo had made a tremendous
stride with its Masimo SET Read-Through Motion and Low Perfusion
technology. Today, Masimo SET is clearly considered the gold
standard in pulse oximetry and has been shown to improve patient care
across the globe. We believe that the new Rainbow Technology will have
similar impact, with the ability to measure carboxyhemoglobin and
methemoglobin noninvasively. We are looking forward to be one of
the first companies to provide our customers with this life saving
monitoring technology."
Joe E. Kiani, Chairman and CEO of Masimo stated; "We are very happy
to expand our long and productive relationship with Atom to bring
Masimo Rainbow SET's new monitoring capabilities to neonatal and infant
care-where Atom excels. This has always been an important segment
of the market for Masimo. Not only because they are the most
challenging patient population, but because having the ability to make
an impact on neonates' lives provides a longer benefit than for
any other patient population. We continue to focus our efforts
heavily in neonatal and infant monitoring as evidenced by innovations
like our Blue sensor, which is specially designed to monitor cyanotic
babies with very low oxygen saturation and children with congenital
heart defects, and our Newborn sensor designed for newborn
resuscitation and examination."
About Atom Medical Corporation
Atom Medical has
an active and strong sales network is made up of over 50 overseas
distributors who market, sell, and service Atom's name brand perinatal
products to hospitals and clinicians in over 90 countries. In addition,
long term relationships with over ten international medical
manufacturers ensure that local clinical needs can be met with the
latest imported medical products. Atom Medical will continue its
commitment to providing the finest in medical products and care to its
worldwide customers.
About Masimo
Masimo develops innovative
monitoring technologies that significantly improve patient care-helping
solve "unsolvable" problems. In 1995, the company debuted Read-Through
Motion and Low Perfusion pulse oximetry, known as SET, and with it
virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent
clinical studies have confirmed that Masimo SET technology allows
clinicians to accurately monitor blood oxygen saturation in critical
care situations-establishing the technology as the "gold standard"
pulse oximetry and substantially contributing to improved patient
outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse
CO-Oximetry, which, for the first time, noninvasively monitors the
level of carbon monoxide and methemoglobin in the blood, allowing early
detection and treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications." Additional information about Masimo and its products
may be found at www.masimo.com.
Contact:
Tom McCall, Masimo Corporation
Phone: 949-297-7075
Email: tmccall@masimo.com
Masimo, SET, Signal Extraction Technology, Radical,
Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications are
registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet, SpHb, PVI,
and Pulse CO-Oximeter are trademarks of Masimo Corp.